-
Imatinib mesylate treatment has dramatically altered clinical outcomes for patients with CML and the question has arisen whether those prognostic factors shown to be relevant in the pre-imatinib era remain so today. This report from M.D. Anderson would suggest that although treatment responses have improved across the board, bone marrow fibrosis remains a significant indicator of lower treatment response and shorter survival.
-
To Americans who donate blood or buy life insurance, the routine HIV test long has been a part of the process. For pregnant women, it's increasingly a part of their prenatal care. But to the millions of Americans who visit an emergency room or sexually-transmitted disease (STD) clinic each year, HIV screening has been offered as a slightly inconvenient add-on health feature.
-
Even with computerized patient records, a hospital located in an ethnically diverse area of the country had medication errors among HIV patients.
-
The FDA, on Oct. 5, 2006, granted tentative approval for didanosine (ddI) for Oral Solution (Pediatric Powder), 10 mg/mL, manufactured by Aurobindo Pharma Limited Inc., of Hyderabad, India.
-
When Michigan public health officials reviewed HIV counseling and testing programs, they concluded they had penetrated as deeply as possible into the communities they served, with about 400 test sites statewide, and yet it seemed the program's effectiveness had reached a plateau.
-
A definite marker that explains HIV dementia remains elusive, but investigators recently found a possible explanation within viral genetic differences.
-
Budgetary problems in funding antiretroviral drugs, which have been growing over the past five years, have led to a situation in which perhaps tens of thousands of HIV/AIDS patients know their status but are not in treatment because they have given up on the system, experts say.
-
HIV treatment and care have been so successful in resource wealthy nations that one unintended byproduct has been that clinicians are less focused on patients' comfort and quality of life than they were when so many of their patients were dying.
-
Researchers continue to study the use of a chemoprophylaxis for the prevention of HIV infection among at-risk groups around the globe, but the results public health officials hope to find remain elusive.
-
Africa remains the hardest hit of the worldwide HIV/AIDS pandemic, accounting for 64 percent of all people living with HIV/AIDS, while only having 10 percent of the world's population, an expert says.
